CLAIMS

1. A tungsten (VI) salt or a solvate thereof, for use thereof for the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique in a mammal.

2. The tungsten (VI) salt according to claim 1, where the mammal is a human.

3. The tungsten (VI) salt according to any one of claims 1 and 2, where said salt is administered in a daily dose between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the female mammal.

4. The tungsten (VI) salt according to any one of claims 1 to 3, where said salt comprises a tungsten (VI) anion and a pharmaceutically, veterinary or dietetically acceptable cation.

5. The tungsten (VI) salt according to any one of claims 1 to 4, where the cation is an alkaline or alkaline earth cation.

6. The tungsten (VI) salt according to any one of claims 1 to 5, **characterized in that** the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.

7. The tungsten (VI) salt according to claim 6, **characterized in that** the cation is sodium.

8. The tungsten (VI) salt according to claim 6, where the cation is zinc.

9. The tungsten (VI) salt according to any one of claims 1 to 8, **characterized in that** the tungsten (VI) anion is selected from WO_4^{2-}, HWO_4^-, $W_2O_7^{2-}$ and $HW_2O_7^-$ ions.

10. The tungsten (VI) salt according to claim 9, characterized in that the anion is WO_4^{2-}.

11. The tungsten (VI) salt according to any one of claims 1 to 10, where the solvate is dihydrate.

12. The tungsten (VI) salt according to any one of claims 1 to 12, where the non-diabetic female mammal is selected from the group of mammals that require restoring and/or promoting ovulation, improving oocyte or embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriumsis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.

13. A composition comprising a tungsten (VI) salt or a solvate thereof as defined in any of claims 1 to 12, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, for the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique applied to a mammal.

14. The composition according to claim 13, **characterized in that** the excipient or vehicle is pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition for the treatment of infertility in a non-diabetic female mammal.

15. The composition according to claim 13, **characterized in that** the excipient or vehicle is pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition for increasing the efficacy of an assisted reproductive technique applied to a mammal.

16. The composition according to any one of claims 14 or 15, **characterized in that** it is in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.

17. The composition according to claim 13, **characterized in that** it is a food

composition for favoring normal reproduction and fertility in a non-diabetic female mammal.

18. The composition according to claim 17, **characterized in that** the composition is a liquid composition or a beverage.

19. The composition according to claim 17, **characterized in that** the composition is a solid composition.

20. The composition according to claim 17, **characterized in that** the food composition is a nutritional supplement or complement.

21. The composition according to any one of claims 13 to 20, **characterized in that** it comprises sucrose.

22. Use of a tungsten (VI) salt or a solvate thereof as defined in any of claims 1 to 12, for the preparation of a medicinal product for the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal or for increasing the efficacy of an assisted reproductive technique applied to a mammal.

23. A method for the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal or for increasing the efficacy of an assisted reproductive technique applied to a mammal, which comprises administering a therapeutically effective amount of a tungsten (VI) salt or a solvate thereof as defined in any of claims 1 to 12.

CLAIMS

1. Use of a tungsten (VI) salt or a solvate thereof, for the manufacture of a medicament for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique in a mammal.

2. The use of a tungsten (VI) salt according to claim 1, where the mammal is a human.

3. The use of a tungsten (VI) salt according to claim 1 or 2, where said salt is administered in a daily dose between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the mammal.

4. The use of a tungsten (VI) salt according to any one of claims 1 to 3, where said salt comprises a tungsten (VI) anion and a pharmaceutically, veterinary or dietetically acceptable cation.

5. The use of a tungsten (VI) salt according to any one of claims 1 to 4, where the cation is an alkaline or alkaline earth cation.

6. The use of a tungsten (VI) salt according to any one of claims 1 to 5, characterized in that the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.

7. The use of a tungsten (VI) salt according to claim 6, characterized in that the cation is sodium.

8. The use of a tungsten (VI) salt according to claim 6, where the cation is zinc.

9. The use of a tungsten (VI) salt according to any one of claims 1 to 8, characterized in that the tungsten (VI) anion is selected from WO_4^{2-}, HWO_4^-, $W_2O_7^{2-}$ and $HW_2O_7^-$ ions.

10. The use of a tungsten (VI) salt according to claim 9, characterized in that the anion is WO_4^{2-}.

11. The use of a tungsten (VI) salt according to any one of claims 1 to 10, where the solvate is dihydrate.

12. The use of a tungsten (VI) salt according to any one of claims 1 to 11, where the mammal is selected from the group of mammals that require restoring and/or promoting ovulation, improving oocyte or embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary axis impairment, including polycystic ovarian syndrome,

metabolic syndrome, hyperprolactinemia, endometriumsis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.

13. Use of a composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, for the manufacture of a medicament for favoring normal reproduction and fertility in a non-diabetic female mammal, or for improving the efficacy of an assisted reproductive technique applied to a mammal.

14. The use of a composition according to claim 13, characterized in that the excipient or vehicle is pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition for the manufacture of a medicament for increasing the efficacy of an assisted reproductive technique applied to a mammal.

15. The use of a composition according to claim 13 or 14, characterized in that the medicament is in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.

16. The use of a composition according to claim 13, characterized in that it is for the manufacture of a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal.

17. The use of a composition according to claim 17, characterized in that the composition is a liquid composition or a beverage.

18. The use of a composition according to claim 17, characterized in that the composition is a solid composition.

19. The use of a composition according to claim 17, characterized in that the food composition is a nutritional supplement or complement.

20. The use of a composition according to any one of claims 13 to 19, characterized in that the composition comprises sucrose.